Peter M. Strumph
Director/Board Member at Amygdala Neurosciences, Inc.
Peter M. Strumph active positions
| Companies | Position | Start | End |
|---|---|---|---|
Amygdala Neurosciences, Inc.
 Amygdala Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Amygdala Neurosciences, Inc. is a biopharmaceutical company. The firm focuses on improving public health by developing and commercializing therapy to treat substance use disorders. Its development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. The company was founded by Lou Lange, Ivan Diamond, Peter Strumph, Brent Blackburn, and Adrienne MacMillan in 2015 and is headquartered in San Francisco, CA. | Director/Board Member | 2015-12-31 | - |
| Chief Executive Officer | 2014-12-31 | - | |
| Founder | 2014-12-31 | - | |
| President | 2014-12-31 | - |
Career history of Peter M. Strumph
Former positions of Peter M. Strumph
| Companies | Position | Start | End |
|---|---|---|---|
| CODEXIS, INC. | Chief Executive Officer | 2012-02-19 | 2012-02-21 |
| Corporate Officer/Principal | 2010-06-28 | 2012-02-19 | |
| President | 2010-06-27 | 2012-06-12 | |
| CAPRICOR THERAPEUTICS, INC. | President | 2007-08-31 | 2009-06-09 |
| Nile Therapeutics, Inc. /Old/ | President | 1996-06-16 | 2007-10-10 |
CV Therapeutics, Inc.
 CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Chief Operating Officer | 1996-12-31 | 2006-12-31 |
| PORTOLA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2013-03-31 | - |
Biogen MA, Inc.
 Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | - | - |
Training of Peter M. Strumph
| The Wharton School of the University of Pennsylvania | Masters Business Admin |
| University of Pennsylvania | Undergraduate Degree |
Statistics
International
| United States | 10 |
Operational
| President | 4 |
| Corporate Officer/Principal | 3 |
| Chief Executive Officer | 2 |
Sectoral
| Health Technology | 7 |
| Consumer Services | 3 |
| Process Industries | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 2 |
|---|---|
| CAPRICOR THERAPEUTICS, INC. | Health Technology |
| CODEXIS, INC. | Process Industries |
| Private companies | 5 |
|---|---|
| Nile Therapeutics, Inc. /Old/ | Health Technology |
CV Therapeutics, Inc.
CV Therapeutics, Inc. BiotechnologyHealth Technology CV Therapeutics™ is a biopharmaceutical company focused on the application of molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases | Health Technology |
Biogen MA, Inc.
Biogen MA, Inc. BiotechnologyHealth Technology Biogen MA, Inc. is a biotechnology company principally engaged in discovering and developing drugs for human healthcare through genetic engineering. The company’s research and development activities used to focus on novel products for multiple sclerosis, inflammatory, respiratory, kidney and cardiovascular diseases, developmental biology and gene therapy. The company was founded by Daniel D. Adams in 1976 and is headquartered in Cambridge, MA. | Health Technology |
Portola Pharmaceuticals LLC
 Portola Pharmaceuticals LLC Pharmaceuticals: MajorHealth Technology Portola Pharmaceuticals, Inc. engaged in the development and commercialization of novel therapeutics in the areas of thrombosis, other hematologic disorders, and inflammation. It offers Andexxa and Bevyxxa medicines. The company was founded by Charles J. Homcy and David R. Philips on September 2, 2003 and is headquartered in South San Francisco, CA. | Health Technology |
Amygdala Neurosciences, Inc.
Amygdala Neurosciences, Inc. Pharmaceuticals: MajorHealth Technology Amygdala Neurosciences, Inc. is a biopharmaceutical company. The firm focuses on improving public health by developing and commercializing therapy to treat substance use disorders. Its development programs include treatment and prevention of opioid, nicotine, alcohol and cocaine use disorders. The company was founded by Lou Lange, Ivan Diamond, Peter Strumph, Brent Blackburn, and Adrienne MacMillan in 2015 and is headquartered in San Francisco, CA. | Health Technology |
- Stock Market
- Insiders
- Peter M. Strumph
- Experience
